Form 4: Fate Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Fate Therapeutics CEO, Bahram Valamehr, sold 8,705 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- Bahram Valamehr, the President and CEO of Fate Therapeutics, sold 8,705 shares of common stock on January 10, 2025.
- The sale was executed at a weighted average price of $1.54 per share, with individual prices ranging from $1.51 to $1.62.
- This transaction was not a discretionary trade but rather a 'sell to cover' transaction to meet tax withholding obligations.
- The shares sold were related to the vesting of restricted stock units (RSUs) granted in 2021 and 2022.
- Following the transaction, Valamehr directly owns 349,364 shares of Fate Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment about the company's performance or future prospects.
Management Comments
- The sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through 'sell to cover' transactions and do not represent discretionary trades by the Reporting Person.
Industry Context
This type of transaction is common for executives who receive stock-based compensation, as they often sell shares to cover the taxes due upon vesting.
Comparison to Industry Standards
- Many executives at publicly traded companies use 'sell to cover' transactions to manage tax liabilities associated with stock-based compensation.
- The sale of shares by the CEO is a routine event and does not necessarily indicate a change in the company's outlook or the executive's confidence in the company.
- Similar transactions are regularly reported by executives at comparable biotech companies.
Stakeholder Impact
- The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant given the nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 01/20/2021 | Date of RSU grant related to some of the shares sold. |
| 01/25/2022 | Date of RSU grant related to some of the shares sold. |
| 01/10/2025 | Date of the stock sale transaction. |
| 01/13/2025 | Date of the filing of the SEC Form 4. |
Keywords
Fate Therapeutics, Bahram Valamehr, stock sale, tax obligations, restricted stock units, RSUs, insider trading, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.